Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | TK2 | O00142 | 10/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2639023 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL445633 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2639649 | 0.88 | TK1 (0.49) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL8997797 | 0.88 | TK1 (0.49) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL8997787 | 0.88 | TK1 (0.49) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL3691195 | 0.82 | TK1 (0.60) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL8997855 | 0.82 | PYGM (0.52) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL8997858 | 0.82 | PYGM (0.52) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2639231 | 0.82 | PYGM (0.52) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL9284740 | 0.82 | TK1 (0.60) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2012-08-30 | — | — | US | claimed |
| EP-2280690-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | Nanobio Corporation (US) | 2011-02-09 | — | — | EP | claimed |
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2010-03-25 | — | — | US | claimed |
| WO-2009129470-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-22 | — | — | WO | claimed |
| EP-0806956-B1 | USE OF 5'SUBSTITUTED NUCLEOSIDES TO PROVIDE RESISTANCE IN CYTOSTATIC TREATMENT | RESPROTECT GMBH (DE) | 2002-08-28 | — | — | EP | claimed |
| EP-0806956-A1 | USE OF 5'SUBSTITUTED NUCLEOSIDES TO PROVIDE RESISTANCE IN CYTOSTATIC TREATMENT AND MEDICAMENTS CONTAINING SAID NUCLEOSIDES | FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 1997-11-19 | — | — | EP | claimed |
| WO-1996023506-A1 | USE OF 5'SUBSTITUTED NUCLEOSIDES TO PROVIDE RESISTANCE IN CYTOSTATIC TREATMENT AND MEDICAMENTS CONTAINING SAID NUCLEOSIDES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 1996-08-08 | — | — | WO | claimed |
| US-5356882-A | Treating herpes virus | UNIVERSITY OF BIRMINGHAM (GB) | 1994-10-18 | — | — | US | claimed |
| WO-1994005686-A1 | ANOMERISATION PROCESS | UNIVERSITY OF BIRMINGHAM (GB) | 1994-03-17 | — | — | WO | claimed |
| EP-0409575-A1 | Antiviral pyrimidine nucleosides | THE UNIVERSITY OF BIRMINGHAM (GB) | 1991-01-23 | — | — | EP | claimed |
| WO-2013130535-A1 | TOPICAL DELIVERY OF HORMONAL AND NON HORMONAL NANO FORMULATIONS, METHODS OF MAKING AND USING THE SAME | NEWGEN BIOPHARMA CORPORATION (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130224268-A1 | TOPICAL DELIVERY OF HORMONAL AND NON HORMONAL NANO FORMULATIONS, METHODS OF MAKING AND USING THE SAME | NEWGEN BIOPHARMA CORP. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2012-08-30 | — | — | US | disclosed |
| US-20120064136-A1 | ANTI-AGING AND WRINKLE TREATMENT METHODS USING NANOEMULSION COMPOSITIONS | NANOBIO CORPORATION | 2012-03-15 | — | — | US | disclosed |
| EP-2280690-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | Nanobio Corporation (US) | 2011-02-09 | — | — | EP | disclosed |
| US-5521163-A | TREATMENT OF HERPES VIRUS WITH 1'-DEOXY-5-ETHYL-4'-THIO-BETA URIDINE | UNIVERSITY OF BIRMINGHAM (GB) | 1996-05-28 | — | — | US | disclosed |
| US-5356882-A | Treating herpes virus | UNIVERSITY OF BIRMINGHAM (GB) | 1994-10-18 | — | — | US | disclosed |
| WO-1994005686-A1 | ANOMERISATION PROCESS | UNIVERSITY OF BIRMINGHAM (GB) | 1994-03-17 | — | — | WO | disclosed |
| WO-1991001326-A1 | ANTIVIRAL PYRIMIDINE NUCLEOSIDES | UNIVERSITY OF BIRMINGHAM (GB) | 1991-02-07 | — | — | WO | disclosed |
| EP-0409575-A1 | Antiviral pyrimidine nucleosides | THE UNIVERSITY OF BIRMINGHAM (GB) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | TK1 18/4885CYP1A2 4640/4885CYP3A4 4587/4885 |
| US-20130224268-A1 | TOPICAL DELIVERY OF HORMONAL AND NON HORMONAL NANO FORMULATIONS, METHODS OF MAKING AND USING THE SAME | SHBG, NR5A1, CYP19A1 | TK1 3205/4885CYP1A2 666/4885CYP3A4 1522/4885 |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | TK1 18/4885CYP1A2 4640/4885CYP3A4 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.